BACKGROUND: Diagnosis of fetal heart failure depends primarily on fetal ultrasonography assessment. Our recent study demonstrated that plasma natriuretic peptide levels in umbilical cord blood were correlated with the severity of heart failure in fetuses with congenital heart defects or arrhythmias. However, percutaneous umbilical blood sampling is an invasive procedure, and therefore, less or noninvasive biomarkers reflecting fetal heart failure are required. OBJECTIVE: The aim of this study was to investigate the possibility of whether maternal serum biomarkers can diagnose fetal heart failure in fetuses with congenital heart defects or arrhythmias. STUDY DESIGN: This exploratory cross-sectional study was conducted at a tertiary pediatric cardiac center. A total of 50 singletons with fetal congenital heart defects or arrhythmias and 50 controls who were registered in the National Cerebral and Cardiovascular Center Biobank from 2013 to 2016 were included. Maternal serum samples obtained during the third trimester were analyzed for 2 hormones and 36 cytokines using the Bio-Plex Pro Human Cancer Biomarker panels 1 and 2. We comprehensively analyzed the association between maternal serum biomarkers and ultrasonography findings or fetal arrhythmia status. Fetal heart failure was defined as a cardiovascular profile score 7. RESULTS: Of 37 fetuses with congenital heart defects, heart failure was found in 1 case of tricuspid valve dysplasia with moderate tricuspid regurgitation. Of 13 fetuses with arrhythmias, 5 had heart failure at 28e33 weeks of gestation. Maternal serum cytokine and hormone concentrations were compared between patients with and without fetal heart failure at 28e33 weeks of gestation (n ¼ 6 and n ¼ 61, respectively). Sixty-one fetuses without heart failure consisted of 10 with congenital heart defect, 6 with arrhythmia, and 45 controls. Maternal serum concentrations of tumor necrosis factor-a, interleukin-6, soluble Fas ligand, transforming growth factor-a, and vascular endothelial growth factor-D were significantly higher when fetuses had heart failure than when they did not (P < .05), whereas maternal serum concentrations of heparinbinding epidermal growth factor-like growth factor were significantly lower when fetuses had heart failure than when they did not (P < .05). Multivariate analysis showed that maternal serum concentrations of tumor necrosis factor-a, vascular endothelial growth factor-D, and heparinbinding epidermal growth factor-like growth factor were independently associated with fetal heart failure. The cutoff values were as follows: tumor necrosis factor-a, 68 pg/mL (sensitivity of 50.0%, specificity of 93.4%, positive likelihood ratio of 7.6, negative likelihood ratio of 0.5); vascular endothelial growth factor-D, 1156 pg/mL (sensitivity of 50.0%, specificity of 93.4%, positive likelihood ratio of 7.6, negative likelihood ratio of 0.5); and heparin-binding epidermal growth factor-like growth factor, 90 pg/mL (sensitivity of 83.3%, specificity of 83.6%, positive likelihood ratio of 5.1, negative likelihood ratio of 0.2). The combination of these 3 cytokines showed sensitivity of 100%, specificity of 80.3%, positive likelihood ratio of 5.1, and negative likelihood ratio of 0. In the absence of fetal heart failure, concentrations of all maternal serum cytokines and hormones were similar in cases of fetal congenital heart defects and controls, while maternal serum soluble CD40 ligand concentrations were increased only in fetal arrhythmias. CONCLUSION: Maternal serum concentrations of tumor necrosis factor-a, vascular endothelial growth factor-D, and heparin-binding epidermal growth factor-like growth factor were associated with fetal heart failure.
BACKGROUND: Diagnosis of fetal heart failure depends primarily on fetal ultrasonography assessment. Our recent study demonstrated that plasma natriuretic peptide levels in umbilical cord blood were correlated with the severity of heart failure in fetuses with congenital heart defects or arrhythmias. However, percutaneous umbilical blood sampling is an invasive procedure, and therefore, less or noninvasive biomarkers reflecting fetal heart failure are required. OBJECTIVE: The aim of this study was to investigate the possibility of whether maternal serum biomarkers can diagnose fetal heart failure in fetuses with congenital heart defects or arrhythmias. STUDY DESIGN: This exploratory cross-sectional study was conducted at a tertiary pediatric cardiac center. A total of 50 singletons with fetal congenital heart defects or arrhythmias and 50 controls who were registered in the National Cerebral and Cardiovascular Center Biobank from 2013 to 2016 were included. Maternal serum samples obtained during the third trimester were analyzed for 2 hormones and 36 cytokines using the Bio-Plex Pro Human Cancer Biomarker panels 1 and 2. We comprehensively analyzed the association between maternal serum biomarkers and ultrasonography findings or fetal arrhythmia status. Fetal heart failure was defined as a cardiovascular profile score 7. RESULTS: Of 37 fetuses with congenital heart defects, heart failure was found in 1 case of tricuspid valve dysplasia with moderate tricuspid regurgitation. Of 13 fetuses with arrhythmias, 5 had heart failure at 28e33 weeks of gestation. Maternal serum cytokine and hormone concentrations were compared between patients with and without fetal heart failure at 28e33 weeks of gestation (n ¼ 6 and n ¼ 61, respectively). Sixty-one fetuses without heart failure consisted of 10 with congenital heart defect, 6 with arrhythmia, and 45 controls. Maternal serum concentrations of tumor necrosis factor-a, interleukin-6, soluble Fas ligand, transforming growth factor-a, and vascular endothelial growth factor-D were significantly higher when fetuses had heart failure than when they did not (P < .05), whereas maternal serum concentrations of heparinbinding epidermal growth factor-like growth factor were significantly lower when fetuses had heart failure than when they did not (P < .05). Multivariate analysis showed that maternal serum concentrations of tumor necrosis factor-a, vascular endothelial growth factor-D, and heparinbinding epidermal growth factor-like growth factor were independently associated with fetal heart failure. The cutoff values were as follows: tumor necrosis factor-a, 68 pg/mL (sensitivity of 50.0%, specificity of 93.4%, positive likelihood ratio of 7.6, negative likelihood ratio of 0.5); vascular endothelial growth factor-D, 1156 pg/mL (sensitivity of 50.0%, specificity of 93.4%, positive likelihood ratio of 7.6, negative likelihood ratio of 0.5); and heparin-binding epidermal growth factor-like growth factor, 90 pg/mL (sensitivity of 83.3%, specificity of 83.6%, positive likelihood ratio of 5.1, negative likelihood ratio of 0.2). The combination of these 3 cytokines showed sensitivity of 100%, specificity of 80.3%, positive likelihood ratio of 5.1, and negative likelihood ratio of 0. In the absence of fetal heart failure, concentrations of all maternal serum cytokines and hormones were similar in cases of fetal congenital heart defects and controls, while maternal serum soluble CD40 ligand concentrations were increased only in fetal arrhythmias. CONCLUSION: Maternal serum concentrations of tumor necrosis factor-a, vascular endothelial growth factor-D, and heparin-binding epidermal growth factor-like growth factor were associated with fetal heart failure.
T he diagnosis of fetal heart failure remains challenging and relies mainly on fetal ultrasonography assessment. Comprehensive assessments such as the cardiovascular profile (CVP) score have recently been used. 1 The CVP score may be useful in serial evaluations of fetuses at risk with myocardial dysfunction. 2 Our recent study demonstrated that plasma natriuretic peptide levels in umbilical cord blood were correlated with the severity of heart failure in fetuses with congenital heart defects (CHDs) or arrhythmias. 3 Percutaneous umbilical blood sampling is necessary to obtain real-time natriuretic peptide values, but because this is an invasive procedure, less invasive biomarkers reflecting fetal heart failure are required.
The fetus and mother are physiologically linked through the placenta. Mirror syndrome is an unusual pathological condition that manifests as maternal edema subsequent to severe fetal and placental hydrops. 4 Although its pathogenesis and pathophysiology remain unclear, it is possible that cytokines from hydropic placenta may increase maternal vasopermeability. 5 A previous study demonstrated high maternal plasma concentrations of soluble vascular endothelial growth factor receptor-1 (sVEGFR-1), an antiangiogenic factor, in mirror syndrome. 6 Therefore, we hypothesized that maternal cytokine levels might reflect fetal heart failure caused by CHDs or arrhythmias.
The aim of this study was to investigate the possibility of whether maternal serum biomarkers can diagnose fetal heart failure in fetuses with CHDs 
Materials and Methods
This single-center, exploratory, crosssectional study was conducted with the approval of our institutional ethics board (M27-008). Written informed consent was obtained from all the patients.
Singletons prenatally diagnosed with fetal CHD or arrhythmia and registered in the National Cerebral and Cardiovascular Center (NCVC) Biobank between July 2013 and June 2016 were included in this study. Patients were excluded if their fetuses were diagnosed with critical chromosomal abnormalities, such as trisomy 13 or 18, or critical extracardiac anomalies requiring surgical intervention during the neonatal period.
Recruited controls were women whose fetuses had no morphological or chromosomal abnormalities and who were registered in the NCVC Biobank between July 2013 and June 2016. Cases and controls were selected in the order of registration in the NCVC Biobank. Exclusion criteria in both cases and controls also included maternal and obstetrical complications such as chronic hypertension, diabetes mellitus, preeclampsia, and gestational diabetes mellitus.
In the NCVC Biobank, maternal serum samples were routinely collected at 10e14 weeks, 28e33 weeks, and 34e39 weeks of gestation during pregnancy. However, maternal serum samples at 10e14 weeks of gestation were not usually available in patients with fetal CHD or arrhythmia because most of them were referred to the NCVC in the third trimester. Therefore, maternal serum samples at 28e33 weeks and 34e39 weeks of gestation were used in this study.
Our tertiary pediatric cardiac center has an established protocol that is implemented after a prenatal diagnosis of CHD or arrhythmia. 3, 7 Outpatients with fetal CHD or arrhythmia were assessed biweekly by CVP score. Patients were admitted to the hospital and assessed at least weekly with CVP and biophysical profile scores after 37 weeks of gestation or if they have a complication such as threatened labor or fetal growth restriction (FGR). All diagnoses of CHD or arrhythmia were confirmed soon after birth by pediatric cardiologists.
In this study, the CVP score was used to assess fetal heart failure because it is not easy to distinguish types of fetal heart failure, given the fluctuating hemodynamics in various CHDs and arrhythmias. 1, 8 Briefly, it is based on a composite scoring system to grade and serially follow the severity of fetal heart failure using 5 fetal echocardiographic parameters: fetal effusion, venous Doppler findings, heart size, cardiac function, and arterial Doppler findings (Table 1) .
Heart failure severity is rated on a 10 point scale; points are deducted for abnormalities in each component marker. In this study because stratified analysis for severity of fetal heart failure was difficult because of the relatively small sample size, fetal heart failure was defined as a CVP score 7. A CVP score of 6 or 7 is considered to indicate moderate heart failure and 5 represents severe heart failure. 2, 3 Moreover, fetal CHD and a CVP score 7 was at a risk of perinatal death. 8 All fetal arrhythmias were diagnosed using fetal echocardiography (GE Medical Systems, Zipf, Austria) and magnetocardiography (MC-6400; Hitachi High-Technologies Corporation, Tokyo, Japan). 9 Fetal arrhythmias were categorized as tachyarrhythmias, bradyarrhythmias, or nonsustained extrasystoles. Fetal tachyarrhythmias, defined as a ventricular rate !180 beats per minute (bpm), included atrioventricular reentrant tachycardia, ectopic atrial tachycardia (EAT), and atrial flutter (AFL). When fetal tachyarrhythmia was sustained for !50% of the time on monitoring, fetal therapy using digoxin, sotalol, and flecainide was carried out. 10, 11 Fetal bradyarrhythmia consisted of atrioventricular block (AVB) and was defined as a ventricular rate <100 bpm. When fetal bradyarrhythmia was complicated with a fetal ventricular rate <55 bpm and myocarditis, betasympathomimetics and dexamethasone were used. 12, 13 Maternal serum samples were collected in the third trimester and at 1 week after delivery. After chilling maternal blood samples on ice, serum samples were prepared by centrifugation at 1500 Â g for 15 min at 4 C and stored at e80 C until measurement. Serum samples were analyzed for 36 cytokines using the Bio-Plex Pro Human Cancer Biomarker Panels 1 and 2 (Bio-Rad, Hercules, CA) according to the manufacturer's protocol. 14 The threshold of each cytokine was routinely <5 pg/mL.
Human chorionic gonadotropin concentrations were measured using the AIA-PACK chemiluminescence AJOG at a Glance Why was this study conducted? Because less or noninvasive biomarkers reflecting fetal heart failure are required, we investigated whether fetal heart failure could be diagnosed in the maternal circulation.
Key findings
Our study demonstrated that maternal serum concentrations of tumor necrosis factor-a, vascular endothelial growth factor-D, and heparin-binding epidermal growth factor-like growth factor were associated with fetal heart failure.
What does this add to what was known?
For the first time, we showed that maternal serum proinflammatory cytokines and apoptotic and angiogenic factors are potential candidates for predicting fetal heart failure in fetuses with congenital heart defects or arrhythmias. We performed a principal component analysis to analyze the pattern of similarity between observations and the variables. We also conducted univariate and multivariate logistic analyses. The best prediction model was selected using stepwise backward elimination, with P ! .10 as criterion for exclusion, which was adjusted for baseline variables. P < .05 was considered significant in all analyses.
A resampling analysis with 100 iterations was performed to identify the variables that entered into 50% of the logistic regression models to determine the independent predictor of SE (selection criterion: P <.05) using the mfp commands of Stata (StataCorp). Each cutoff value was calculated using receiver-operating characteristic (ROC) analysis. The area under the ROC curve of each variable was calculated using nonparametric analysis with bootstrap method.
Results

Study cohort and baseline characteristics
A total of 50 women with fetal CHDs or arrhythmias and 50 controls were enrolled in the present study ( Figure 1 ). All controls had a fetal CVP score of 10. Except for CVP scores, baseline perinatal characteristics were not significantly different between the 2 groups. Categories of CHDs and arrhythmias are shown in Table 2 . Arrhythmias complicated by CHD were included in the arrhythmia group.
Of 37 fetuses with CHDs, 1 with tricuspid valve dysplasia and moderate tricuspid regurgitation had a CVP score of 7. One fetus with atrioventricular reentrant tachycardia, 5 with AFL, and 2 with EAT demonstrated cardioversion to sinus rhythm following fetal treatment. No fetus with complete AVB had an increase in CVP score in utero despite fetal Reversed end-diastolic UA flow
The CVP score was calculated as follows: the maximum score for the 5 indices was 10, with points deducted according to disease severity. A CVP score of !8 is considered to indicate no or mild heart failure, 6 or 7 moderate heart failure, and 5 severe heart failure.
CAVVR, common atrioventricular valve regurgitation; CHD, congenital heart defect; CTAR, cardiothoracic area ratio; CVP, cardiovascular profile; FS, fractional shortening; MR, mitral valve regurgitation; TR, tricuspid valve regurgitation; UA, umbilical artery.
Miyoshi et al. Maternal serum biomarkers for fetal heart failure. Am J Obstet Gynecol 2019.
FIGURE 1
Study flowchart
The term, 28e33 weeks, indicates cases in which maternal serum was available at 28e33 weeks of gestation. The term, 34e39 weeks, indicates cases in which maternal serum was available at 34e39 weeks of gestation. The term postpartum indicates the case in which maternal serum was available at 1 week after delivery.
CHD, congenital heart defect; CVP, cardiovascular profile.
Original Research OBSTETRICS ajog.org treatment, resulting in a CVP score 7 at 34e39 weeks of gestation in all cases of complete AVB. In summary, 1 fetus with AFL, 2 with EAT, and 2 with complete AVB had fetal heart failure at 28e33 weeks of gestation and 3 with complete AVB had heart failure at 34e39 weeks of gestation. One fetus with complete AVB had a CVP score of 5, and all others had a CVP score of 7. There were no cases of fetal hydrops or mirror syndrome.
Maternal serum biomarkers in cases with fetal heart failure (CVP score £7)
The median interval from blood sampling to freezing was 1 hour, but the interval ranged from 0 to 10 hours in the NCVC Biobank, so we investigated the coefficient of variation in the measured cytokine data for the serum samples processed up to 12 hours after blood sampling. This test of cytokine stability was performed in volunteers to minimize the burden on study participants.
Serum samples from a volunteer pregnant woman and a volunteer adult man were prepared by centrifugation at 1, 2, 4, 6, and 12 hours after blood sampling. Using the 5 serum samples from each individual, we measured a series of cytokines and showed that the coefficient of variation was less than 10% for most cytokines in these serum samples (Supplemental Table 1 ).
Maternal serum cytokine and hormone concentrations were compared between patients with and without fetal heart failure at 28e33 weeks of gestation (n ¼ 6 and n ¼ 61, respectively). Sixtyone fetuses without heart failure consisted of 10 with CHD, 6 with arrhythmia, and 45 controls. Baseline perinatal characteristics were similar in the 2 groups (Supplemental Table 2 ). All maternal examination data, such as peripheral blood, liver function, and renal function, were within normal range in both groups (Supplemental Table 3 ).
The results of principal component analysis are shown in Figure 2 . The first component (25.5%) consisted of interleukin (IL)-6, IL-8, soluble Fas ligand (sFASL), transforming growth factor (TGF)-a, tumor necrosis factor (TNF)-a, and vascular endothelial growth factor (VEGF)-D, which are mainly proinflammatory cytokines and apoptotic factors. The second component (13.6%) consisted of fibroblast growth factor-basic, granulocyte-colony stimulating factor, heparin-binding epidermal growth factorlike growth factor (HB-EGF), VEGF-A, and VEGF-C, which are mainly angiogenic factors.
Maternal serum concentrations of TNF-a, IL-6, sFASL, TGF-a, and VEGF-D were significantly higher when fetal heart failure was present at 28e33 weeks of gestation than when it was not (P < .05) ( Table 3 ). In contrast, maternal serum concentrations of HB-EGF were significantly lower when fetal heart failure was present at 28e33 weeks of gestation than when it was not (P ¼.01). Notably, all 6 of these cytokines were included in the first and second components. 
Hypoplastic left heart syndrome (n ¼ 5)
Cyanotic heart defect (n ¼ 12)
Transposition of the great arteries (n ¼ 5)
Total anomalous pulmonary venous connection (n ¼ 2)
Coarctation of the aorta (n ¼ 4)
Cardiac tumor (n ¼ 1)
a One fetus with complete atrioventricular block had left atrial isomerism. Table 4) . The cutoff values calculated using ROC analysis were as follows (Supplemental Figure) ; TNF-a, 68 pg/mL; VEGF-D, 1156 pg/mL; and HB-EGF, 90 pg/mL. Sensitivity, specificity, likelihood ratio, positive predict value, and negative predict value in addition to the area under the ROC curve of each maternal serum cytokine and their combination in fetal heart failure are shown in Table 5 .
Maternal serum biomarkers in cases without fetal heart failure (CVP score ‡8)
In women without fetal heart failure at 28e33 weeks of gestation, maternal serum cytokine and hormone concentrations were compared among cases of fetal CHD (n ¼ 10), cases of fetal arrhythmia (n ¼ 6), and controls (n ¼ 45). Maternal serum concentrations of soluble human epidermal growth factor receptor 2/neu, soluble CD40 ligand (sCD40L), and plasminogen activator inhibitor-1 were significantly higher in cases of fetal arrhythmia than in cases of fetal CHD (P < .05). Maternal serum HB-EGF concentrations were significantly lower in cases of fetal arrhythmia than in cases of fetal CHD (P ¼ .02).
Maternal serum concentrations of soluble human epidermal growth factor receptor 2/neu and sCD40L were significantly higher in cases of fetal arrhythmia than in controls (P < .05). Additionally, in women without fetal heart failure at 34e39 weeks of gestation, maternal serum cytokine and hormone concentrations were compared among cases of fetal CHD (n ¼ 36), cases of fetal arrhythmia (n ¼ 10), and controls (n ¼ 50). Maternal serum concentrations of sCD40L and VEGF-D were significantly higher in cases of fetal arrhythmia than cases of fetal CHD (P < .05). Maternal serum concentrations of soluble Tei-2, sCD40L, and TGF-a were significantly higher in cases of fetal arrhythmia than in controls (P < .05).
Collectively, these data indicated that maternal serum sCD40L concentrations were significantly higher in cases of fetal arrhythmia than in cases of fetal CHD and controls, both at 28e33 and 34e39 weeks of gestation in the absence of fetal heart failure (P < .05) (Figure 3, A and B) . Conversely, in cases of fetal CHD without heart failure, all maternal serum cytokine and Principal component analysis of maternal serum cytokine and hormone concentrations at 28e33 weeks of gestation To determine which of the original 2 hormones and 36 cytokines were most important, we conducted a principal component analysis, which transforms a number of possibly correlated variables into a smaller number of uncorrelated variables. The first component (25.5%, solid circle) consists of IL-6, IL-8, sFASL, TGF-a, TNF-a, and VEGF-D, which are mainly proinflammatory cytokines and apoptotic factors. The second component (13.6%, dotted circle) consists of FGF-basic, G-CSF, HB-EGF, VEGF-A, and VEGF-C, which are mainly angiogenic factors.
AFP, alpha-fetoprotein; EGF, epidermal growth factor; FGF, fibroblast growth factor; G-CSF, granulocyte-colony stimulating factor; HB-EGF, heparin-binding epidermal growth factor-like growth factor; hCG, human chorionic gonadotropin; HGF, hepatocyte growth factor; IGFBP, insulin-like growth factor binding protein; IL, interleukin; PAI, plasminogen activator inhibitor; PDGF, platelet-derived growth factor; PECAM, platelet and endothelial cell adhesion molecule; PLGF, placental growth factor; sCD40L, soluble CD40 ligand; SCF, stem cell factor; sEGFR, soluble epidermal growth factor receptor; sFASL, soluble Fas ligand; sHER, soluble human epidermal growth factor receptor; sVEGFR, soluble vascular endothelial growth factor receptor; TGF, transforming growth factor; TNF, tumor necrosis factor; uPA, urokinase-type plasminogen activator; VEGF, vascular endothelial growth factor.
TABLE 3
Maternal serum concentrations of cytokines in cases with and without fetal heart failure at 28e33 weeks of gestation (n [ 67) hormone concentrations were similar to controls both at 28e33 and 34e39 weeks of gestation.
Maternal serum biomarkers during pregnancy and postpartum in controls
Trends in maternal cytokine and hormone concentrations during pregnancy and postpartum in controls are shown in Supplemental Table 4 . During pregnancy compared with postpartum, TNF-a, sFASL, and TGF-a levels were higher, HB-EGF and sCD40L levels were lower, and IL-6 and VEGF-D levels were not significantly different.
Comment
Principal findings
Our study demonstrated that maternal serum concentrations of TNF-a, VEGF-D, and HB-EGF were associated with fetal heart failure in fetuses with CHDs or arrhythmias. Furthermore, in fetuses without heart failure, all maternal serum cytokine and hormone concentrations were similar between cases of fetal CHD and controls, while maternal serum sCD40L concentrations were increased in cases of fetal arrhythmia.
Clinical implications
Maternal serum TNF-a concentrations were associated with fetal heart failure. TNF-a is a well-known proinflammatory cytokine that is present at sites of inflammation. 15 Our results suggested that fetal heart failure may be associated with the maternal response to systemic inflammation.
The physiological states of the fetus and mother are closely linked via the placenta. Mirror syndrome, manifesting as maternal pulmonary and skin edema, occurs when fetal heart failure causes both fetal and placental hydrops. 4 Although its pathogenesis and pathophysiology remain unclear, it is possible that cytokines from a hydropic placenta with trophoblastic damage may increase maternal vasopermeability. 5 Our recent study demonstrated that plasma natriuretic peptide levels in umbilical cord blood were correlated with the severity of fetal heart failure. 3 Elevated natriuretic peptide levels are mainly attributable to increases in a The best prediction model was selected using stepwise backward elimination with P ! .10 as the criterion for exclusion, which was adjusted for baseline variables. P < .05 indicates a significant difference; b Percent (%) refers to the reliability determined by the bootstrap validation method. A resampling analysis with 100 iterations was performed to identify the variables that were included in 50% of the logistics regression models. Miyoshi et al. Maternal serum biomarkers for fetal heart failure. Am J Obstet Gynecol 2019. Each cutoff value was calculated using ROC analysis: TNF-a, 68 pg/mL; VEGF-D, 1156 pg/mL; and HB-EGF, 90 pg/mL. Using nonparametric analysis of ROC curve under covariates with the bootstrap method, each AUC was calculated, and then the AUCs for maternal serum cytokines and their combinations were not significantly different compared with the AUC for TNF-a plus VEGF-D plus HB-EGF.
AUC, area under the ROC curve; CI, confidence interval; HB-EGF, heparin-binding epidermal growth factor-like growth factor; NPV, negative predictive value; PPV, positive predictive value; ROC, receiver operating characteristic; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor. Miyoshi et al. Maternal serum biomarkers for fetal heart failure. Am J Obstet Gynecol 2019.
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OBSTETRICS Original Research central venous pressure secondary to arrhythmias or CHD-induced atrioventricular valve regurgitation. Thus, we speculated that increased central venous pressure in fetal heart failure may damage placental trophoblasts and increase proinflammatory cytokines, resulting in the elevation of both maternal and placental vasopermeability. 5 Espinoza et al 6 reported that high maternal sVEGFR-1 concentrations were observed in mirror syndrome. Excess sVEGFR-1 binds to and inactivates VEGF and thereby induces systemic endothelial dysfunction. 16 In this study, fetal heart failure did not induce high sVEGFR-1 and low VEGF levels in maternal serum, but it was associated with maternal systemic inflammatory cytokines such as IL-6 and TNF-a. Therefore, in the future, it is necessary to measure and compare the changes of maternal serum cytokines in patients with more severe fetal heart failure and mirror syndrome.
Maternal serum concentrations of VEGF-D and HB-EGF were also associated with fetal heart failure in this study. VEGF-D and HB-EGF are known to be angiogenic factors that are closely correlated with organ injury and repair. Cells in inflammatory tissue are often damaged and need repair. Maternal concentrations of these cytokines may be altered secondary to trophoblast injury that results in inflammation.
Llurba et al 17 found that an intrinsically angiogenic impairment exists in CHD that appears to be present in both the maternal and fetal circulations. The authors suggested that an imbalance of angiogenic-antiangiogenic factors is associated with developmental defects of the human heart. However, in this study, women whose fetuses had CHD but no heart failure demonstrated that serum concentrations of cytokines, including angiogenic factors, were similar to those of controls. Thus, our results indicate that maternal serum cytokine levels are altered by fetal heart failure rather than by morphological abnormalities of the fetal heart.
In this study, maternal serum sCD40L concentrations were associated with fetal arrhythmias in cases in which the fetuses did not have heart failure. sCD40L is a transmembrane protein that is shed from activated platelets and is involved in the activation of endothelial cells.
Inwald et al 18 found that the binding of sCD40L to platelet CD40L caused CD62P expression and that the release of the contents of a-granules and dense granules participated in the recruitment and activation of leukocytes. However, Henn et al 19 reported that even high levels of sCD40L failed to induce an inflammatory reaction. They concluded that the CD40L-CD40 interaction eventually transforms CD40L to the biologically inactive sCD40L, thereby effectively limiting the inflammatory process in the vascular system. Thus, data on whether sCD40L is capable of eliciting an inflammatory response remain controversial.
Our results showed that in women without fetal heart failure, serum sCD40L concentrations were significantly higher in cases of fetal arrhythmia than in cases of fetal CHD or controls. Even when fetal therapy is not indicated, both fetal tachyarrhythmia and bradyarrhythmia in the absence of heart failure may damage trophoblasts and alter endothelium-platelet interactions.
Study strengths and limitations
The present study had several strengths. First, this was the first study to demonstrate that maternal serum cytokine concentrations may indicate the presence of fetal heart failure. Interestingly, maternal serum cytokine levels were affected not by morphological abnormalities of the developing heart but by fetal heart failure secondary either to an arrhythmia or to CHD-induced atrioventricular valve regurgitation. Second, our center is one of the largest tertiary pediatric cardiac institutions in Japan, and women whose fetuses had a variety of complex CHDs and arrhythmias were included in the study cohort. In addition, all fetuses with CHDs or arrhythmias were diagnosed prenatally with high accuracy, and serial assessment using the CVP score was available. Thus, we were able to unambiguously investigate the relationship between maternal serum cytokine levels and cases of fetal heart failure with identified pathoetiologies.
There were several limitations to the present study, beyond its exploratory nature. First, only the Bio-Plex Pro Human Cancer Biomarker panels 1 and 2 was used to assess the cytokines in this study, and 
Maternal serum sCD40L concentrations
Maternal serum sCD40L concentrations are significantly higher in cases of fetal arrhythmia than in cases of fetal CHD and in controls at 28e33 weeks of gestation (A) and at 34e39 weeks of gestation (B), respectively. Boxes indicate median and IQR, whiskers are range excluding outliers more than 1.5 Â IQR from upper or lower quartile, and circles are outliers. The asterisk indicates the Tukey-Kramer honest significant difference test that was used (P < .05 indicates a significant difference).
CHD, congenital heart defect; IQR, interquartile range; sCD40L, soluble CD40 ligand. Original Research OBSTETRICS ajog.org therefore, it is unclear whether other cytokines can predict fetal heart failure. Second, the most severe cases, namely fetal hydrops or mirror syndrome, were not included in the analysis, partially because of the efficacy of transplacental therapy for fetal arrhythmias. Third, it is difficult to evaluate the correlation between maternal serum biomarker levels and the severity of fetal heart failure or types of CHD and arrhythmia because of the relatively small sample size. Lastly, we have not yet clarified whether maternal serum biomarkers are useful for assessing fetal heart failure prior to the third trimester. Even in normal pregnant women, maternal serum concentrations of some cytokines, such as sVEGFR-1 and placental growth factor, fluctuate during pregnancy. 20, 21 Maternal characteristics and conditions may also influence maternal serum cytokine levels. Therefore, to minimize the biases in this study cohort, we focused on the third trimester and excluded cases with maternal and obstetrical complications.
Conclusions and future research direction
Our study demonstrated that maternal serum concentrations of TNF-a, VEGF-D, and HB-EGF were associated with fetal heart failure. For the first time, we showed that maternal serum proinflammatory cytokines and apoptotic and angiogenic factors are potential candidates for predicting fetal heart failure in fetuses with CHDs or arrhythmias. In the future, larger multicenter prospective cohort studies are needed to clarify whether maternal serum concentrations of TNF-a, VEGF-D, and HB-EGF can assess the severity of heart failure and determine the efficacy of fetal therapy.
As a general issue, the most frequent cause of fetal heart failure is FGR due to placental insufficiency. 22 The pathophysiology of fetal cardiac failure is quite different between FGR on the one hand and CHD or arrhythmia on the other. Thus, it is beneficial to investigate whether heart failure has different maternal biomarker signatures, depending on whether it is caused by FGR vs CHD or arrhythmia. We believe that our results will help optimize the design of future studies to accurately determine whether maternal serum biomarkers can predict fetal heart failure. n grants from the Japan Heart Foundation and the Tsuchiya Memorial Medical Foundation. These funding sources had no involvement in study design; the collection, analysis, and interpretation of data; the writing of the report; and the decision to submit the article for publication.
The authors report no conflict of interest. 
ROC curves of maternal serum cytokines and combination in FHF
The ROC curves of each maternal serum cytokine and their combination in fetal heart failure are shown. = FHF, fetal heart failure; HB-EGF, heparin-binding epidermal growth factor-like growth factor; ROC, receiver operating characteristic; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor. Serum samples from a volunteer pregnant woman and a volunteer adult man were prepared by centrifugation at 1, 2, 4, 6, and 12 hours after blood sampling and stored at e80 C until measurement. The coefficient of variation of each cytokine concentration was calculated using the 5 serum samples from each individual.
EGF, epidermal growth factor; FGF, fibroblast growth factor; G-CSF, granulocyte-colony stimulating factor; HB-EGF, heparinbinding epidermal growth factor-like growth factor; HGF, hepatocyte growth factor; IGFBP, insulin-like growth factor binding protein; IL, interleukin; PAI, plasminogen activator inhibitor; PDGF, platelet-derived growth factor; PECAM, platelet and endothelial cell adhesion molecule; PLGF, placental growth factor; sCD40L, soluble CD40 ligand; SCF, stem cell factor; sEGFR, soluble epidermal growth factor receptor; sFASL, soluble Fas ligand; sHER, soluble human epidermal growth factor receptor; sVEGFR, soluble vascular endothelial growth factor receptor; TGF, transforming growth factor; TNF, tumor necrosis factor; uPA, urokinase-type plasminogen activator; VEGF, vascular endothelial growth factor. Miyoshi et al. Maternal serum biomarkers for fetal heart failure. Am J Obstet Gynecol 2019. SUPPLEMENTAL TABLE 2 Baseline perinatal characteristics in patients with and without fetal heart failure at 28e33 weeks of gestation (n [ 67) 
ajog.org OBSTETRICS Original Research
SUPPLEMENTAL TABLE 3
Baseline maternal examination data in patients with and without fetal heart failure at 28e33 weeks of gestation (n [ 67) a Serum concentrations were significantly reduced after delivery compared with those during pregnancy; b Serum concentrations were significantly increased after delivery compared with those during pregnancy; c Serum concentrations were not significantly different during pregnancy and after delivery.
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